The biotechnology sector has seen a remarkable resurgence, with the State Street SPDR S & P Biotech ETF (XBI) rising nearly 80% and the iShares Biotechnology ETF (IBB) gaining over 40% in the past year, significantly outperforming the S&P 500's 19% increase.
Investors remain optimistic, particularly due to the impending expiration of patents for large pharmaceutical companies, which may spur merger and acquisition activity. Evan McCulloch, lead portfolio manager of the Franklin Biotechnology Discovery Fund (FBDIX), emphasized that M&A activity is a crucial driver for the sector's growth.
The fund has performed well, ranking in the top quartile over multiple time frames, and is currently up more than 18% year-to-date. McCulloch is particularly bullish on Revolution Medicines, whose shares have surged 130% this year following positive Phase 3 trial results for its pancreatic cancer drug, daraxonrasib, which is expected to receive FDA approval soon.
However, McCulloch is adopting a more cautious approach in selecting positions, as many midcap stocks appear fairly priced after the recent rally. Matt Bartolini from State Street Investment Management cautioned that while the XBI has performed well, it remains volatile, with a one-year standard deviation of 19%, compared to 13% for the S&P 500.
Despite potential volatility, improving M&A trends and the sector's alignment with artificial intelligence advancements are seen as positive indicators for future growth. Douglas Yones, CEO of Direxion, expressed confidence in the biotech sector's long-term growth, anticipating a geometric increase in healthcare and pharmaceutical advancements over the next five to ten years